Were all the director nominees elected to the board?

Yes, all 13 director nominees presented at the Annual Meeting of Shareholders were elected to the Company's Board of Directors. They all received a substantial majority of the votes cast in their favor.

What was the outcome of the advisory vote on executive compensation?

Shareholders provided a non-binding advisory vote to approve the compensation of Merck's named executive officers, with approximately 91.30% of the votes cast in favor. The frequency for such future advisory votes was overwhelmingly determined to be 'one year' (99.98% of votes cast).

Were the shareholder proposals supported by the majority of shareholders?

No, the majority of shareholder proposals, including those related to business operations in China, COVID-19 product access, political spending, patents, congruency reports, and an independent board chairman, were not approved. They received significant opposition, with the 'Against' votes far outweighing the 'For' votes in each case.

How did shareholders vote on the ratification of the independent auditor?

Shareholders strongly supported the ratification of the appointment of Merck's independent registered public accounting firm for 2023, with approximately 94.27% of the votes cast voting in favor.

MRK 8-K: Shareholder Matters

Summary

Merck & Co., Inc. (MRK) filed an 8-K on May 25, 2023, detailing the results of its Annual Meeting of Shareholders held on May 23, 2023. The primary focus of the filing is the shareholder votes on various proposals, including the election of directors, executive compensation, and several shareholder-submitted proposals. All director nominees were overwhelmingly elected, and shareholders approved the appointment of the independent registered public accounting firm for 2023 with strong support. Investors will note that shareholders overwhelmingly supported an annual advisory vote on executive compensation and favored an "one year" frequency for future advisory votes on executive compensation. However, a significant number of shareholder proposals, concerning topics such as operations in China, access to COVID-19 products, political spending, patents, congruency reports, and board independence, were largely rejected by the majority of votes cast, indicating continued alignment between the board's recommendations and the majority shareholder sentiment on these specific issues.

Key Highlights

1All 13 nominated directors were elected to the Board of Directors with high percentages of "For" votes, generally above 91%, with most exceeding 97%.
2Shareholders provided strong advisory approval for the compensation of named executive officers, with 91.30% voting in favor.
3The frequency of advisory votes on executive compensation will remain "one year," as supported by 99.98% of the votes cast.
4The appointment of the Company's independent registered public accounting firm for 2023 was ratified with a high level of shareholder approval (94.27%).
5Shareholder proposals regarding business operations in China, access to COVID-19 products, indirect political spending, patents and access, congruency reports, and an independent board chairman were all significantly opposed by the majority of votes cast.
6Director Robert M. Davis received the lowest percentage of 'For' votes among nominees at 91.52%, though still a strong majority.
7Director Patricia F. Russo also received a comparatively lower percentage of 'For' votes at 86.11% among the director nominees.

Merck & Co., Inc. 8-K Report, Shareholder Vote Results (May 26, 2023)

Summary

Key Highlights

Frequently Asked Questions